Anlon Healthcare IPO: Price Band, Analysis, Allotment And GMP

Anlon Healthcare IPO - Company Analysis

Anlon Healthcare IPO, a Mainboard IPO, is a bookbuilding issue of Rs. 121.03 Cr (~1.33 crore Shares) by Anlon Healthcare Ltd., which was incorporated in 2013 and is a chemical manufacturing firm that produces active pharmaceutical ingredients (APIs) and pharma intermediates.

The company produces active pharmaceutical ingredients (used in formulations for medications, nutraceuticals, personal care, and animal health products) and high-purity pharmaceutical intermediates (for the manufacturing of APIs).

By Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP, the company manufactures pharmaceutical intermediates and APIs for medications, nutraceuticals, personal care, and veterinary goods.

The company now offers custom manufacturing for complicated chemicals, surpassing purity criteria and lowering impurities to satisfy particular customer needs, in addition to producing Pharma Intermediates and APIs following international standards.

The company's portfolio consists of 49 products undergoing laboratory testing, 28 in the pilot stage, and 65 commercialized products.

Goods:

Methyldesloratadine, ketonitrile, and cyanoethylbenzoic acid are essential raw materials or advanced intermediates used in the production of APIs.

The company's APIs provide therapeutic effects and are essential parts of pharmaceutical products. They are utilized in nutraceuticals, personal care, and veterinary goods, as well as in formulations such as tablets, capsules, ointments, and syrups.

 

Anlon Healthcare IPO Details

The Anlon IPO open date is from Aug 26 to Aug 29, with IPO allotment on Sep 01, refund initiation on Sep 02, 2025.

The Rs. 121.03 Cr mainline IPO comprises a fresh issue of 1.33 Cr Shares.

The Anlon Healthcare IPO listing date might be on Wednesday, 03 September 2025, and it will be listed at the BSE and NSE. The Anlon Healthcare IPO price band is Rs. 86 to Rs. 91 for each Share. 

Events	Date
IPO Opening Date	Aug 26, 2025
IPO Closing Date	Aug 29, 2025
IPO Allotment Date	Sep 01, 2025
Refund Initiation	Sep 02, 2025
Tentative IPO Listing Date	Sep 03, 2025

 

Industry Outlook

The Indian pharmaceutical sector is the 3rd largest in terms of the quantity of medications produced. The CAGR for the Indian pharmaceutical industry was 9.9% between FY 2019 - FY 2024.

If you want to apply for the IPO, click to open a Demat Account.

 

 

Company Financial 

(Amount in Cr)

Period	31 Jan 2025	31 Mar 2024	31 Mar 2023
Total Assets	160.96	128	111.55
Total Revenue	77.37	66.69	113.12
PAT	11.96	9.66	5.82
Net Worth	71.86	21.03	7.37
Reserves and Surplus	32.01	5.03	-4.63
Total Borrowing	62.39	74.56	66.39

Cash Flows

The cash flows for various activities are shown below:

(Amount in millions)

Net Cash Flow In Multiple Activities	31 Jan 2025	31 Mar 2024	31 Mar 2023
Net Cash Flow Operating Activities	(2,721.80)	(322.60)	(284.97)
Net Cash Flow Investing Activities	281.74	(336.90)	(33.49)
Net Cash Flow Financing Activities	2358.73	824.58	226.59

 

Revenue Bifurcation 

Industry-wise Revenue Breakdown

 

Geography-wise Revenue Breakdown

 

State-wise Revenue Breakdown

(Source RHP)

 

The Objective of The Issue

• The proposed expansion requires funding for capital expenditures. ~ Rs. 30.72 Cr.

• Repayment in full, in part, or in advance of certain outstanding secured loans that the company has taken out. ~ Rs. 5 Cr.

• Paying for the company's working capital needs. ~ Rs. 43.15 Cr.

• General corporate purposes.

Click to check the IPO application status.

 

Listed Peers of Anlon Healthcare Ltd.

Company Name	Face Value (Rs. per Share)	EPS (Rs.)	P/E (x)
Kronox Lab Sciences Limited	10	5.81	26.72
AMI Organics Limited	10	11.91	197.70
Supriya Lifeciences Limited	2	14.80	49.52

Valuation

Metric	Value
ROCE	21.93%
Debt/Equity	0.73
PAT Margin	17.06%
EBITDA	26.88%
Price to Book Value	4.51
RoNW	25.21%

 

Evaluation of P/E Ratio

Considering the period of FY 2024, with an EPS of Rs. 6.68 from the last year, the resulting P/E ratio is 13.62x. When compared with the industry’s average P/E of 105.93x, it indicates an undervaluation (on a P/E ratio basis only). Hence, the price of the Share seems fairly priced for the investors.

Explore the Shreeji Shipping Global IPO.

IPO's Strengths 

• Robust product line and expandable company.

• An experienced management team and strong promoters.

• Strict product standards and lengthy customer approval periods result in high entry and exit barriers.

• For quality control, use internal testing, quality assurance, and control.

• Prioritize safety, health, the environment, and quality.

 

IPO’s Weaknesses 

• A heavy reliance on contracts with the government.

• Businesses require a lot of working capital.

• The risk of geographic concentration

• A heavy burden of debt and liabilities.

 

Anlon Healthcare IPO GMP 

Anlon Healthcare IPO GMP today has not started yet as of 21 Aug 2025, while writing this information.

Anlon Healthcare Limited IPO Summary

IPO Opening & Closing Date	Aug 26, 2025 to Aug 29, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 86 to Rs. 91
Lot Size	164 Shares
Issue Size	1,33,00,000 Shares (Rs. 121.03 Cr)
Offer for Sale	-
Fresh Issue	1,33,00,000 Shares (Rs. 121.03 Cr)
Listing At	BSE, NSE
Issue Type	Book Built Issue IPO
Registrar	Kfin Technologies Ltd.

 

 

Anlon Healthcare IPO Lot Size

The IPO allows retail investors to invest in a minimum and maximum of 1 Lot (164 Shares) amounting to Rs. 14924 and 13 Lots (2132 Shares) amounting to Rs. 194012, respectively, while for S-HNI investors, the minimum Lot is 14 (2296 Shares) amounting to Rs. 208936.

Minimum Lot Investment (Retail)	1 Lot
Maximum Lot Investment (Retail)	13 Lots
SHNI (Minimum)	14 Lots
SHNI (Maximum)	67 Lots
BHNI (Minimum)	68 Lots

Anlon Healthcare IPO Reservation

Institutional Share Portion	75%
Retail Investors' Share Portion	10%
Non-Institutional Shares Portion	15%

 

Anlon Healthcare IPO Allotment Status

To check the Anlon Healthcare IPO allotment status, visit the official Registrar’s website or the BSE website. Below are the website links for you.

Using Registrar’s Website - Kfin IPO allotment status

Using BSE Website - ​BSE IPO allotment status

 

Promoters And Management of Anlon Healthcare Ltd.

• Punitkumar R. Rasadia

• Meet Atulkumar Vachhani

• Mamata Punitkumar Rasadia. 

Pre-Issue Promoter Shareholding	70.26%
Post-Issue Promoter Shareholding	-

 

Anlon Healthcare IPO Lead Managers

• Interactive Financial Services Ltd.   

 

 

Dividend Policy

The company has not paid a dividend during the last three fiscal years.

Conclusion

With a solid product portfolio, seasoned promoters, and outstanding financial results, Anlon Healthcare IPO exposes investors to the expanding pharmaceutical and API industries. The IPO has an undervalued P/E. However, its working capital intensity, debt levels, and sector-specific risks need to be carefully considered.

 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.